Norepinephrine, also known as noradrenaline, was discovered in 1946 in the USA and by 1950 it was approved for general medical use. Norepinephrine is the international non-proprietary name (INN) while noradrenaline is the British Approved Name (BAN). This medication is given to treat the people suffering from hypotension. It is the same chemical compound as the hormone and neurotransmitter present in our body. Norepinephrine is given in hospitals or emergency room settings through slow injection into the patient’s vein. People receive norepinephrine dose for several days until their body responds to the medication. After that, a healthcare provider regularly and closely monitors the patient’s blood pressure, breathing, and other vital signs. Norepinephrine is an FDA approved drug for blood pressure control in certain acute hypotensive states, as well as a potential adjunct in the treatment of cardiac arrest with profound hypotension.
The norepinephrine drug market is anticipated to record a significantly high CAGR over the forecast period, i.e., 2020-2028. In 2020, the market is growing at a stable rate owing to the rising prevalence of low blood pressure condition globally, along with the improved efficacy and predictive pharmacological properties of norepinephrine drug. On the other hand, the rapidly increasing geriatric population is driving the market growth further. The norepinephrine drug market is segmented by product, by application, by end-user, and by region. Based on the end-user, the norepinephrine market is segmented into hospitals, private clinics, ambulatory surgery centers, and others, out of which, the hospital segment accounts for the largest market share on account of the increase in the number of elderly patients every year. Elderly in-patients are higher than the patients in-home care settings owing to the intensive monitoring and caring routine of elderly patients at hospitals. Norepinephrine is a strong drug and excellent at increasing systematic vascular resistance therefore, it is globally used as first-line agents to treat hypotension in patients with acute circulatory failure. Norepinephrine is considered to be better than dopamine owing to its properties and fewer adverse side-effects. All these factors are expected to thrive in the norepinephrine market in the coming years.
Norepinephrine drug has some exceptional advantages over other alpha-adrenergic agonists, it is considered to have more predictive pharmaceutical properties. This predictive quality, combined with some of its beta-adrenergic agonist (which improves cardiac function comparative to pure alpha-adrenergic agonists), makes norepinephrine a widely used sympathomimetic drug. It is commonly used in intensive care units to treat hypotension. Additionally, it is the first-line agent for treating hypotension. This advantage is anticipated to provide lucrative business opportunities for norepinephrine drugs market during the forecast period. CLICK TO DOWNLOAD SAMPLE REPORT
According to a 2017 UN report on World Population Ageing, the global population aged 60 years or over totalled 962 million in 2017, more than twice as large as in 1980 when there were 382 million older persons worldwide. The number of geriatric individuals is expected to double again by 2050 when it is projected to reach nearly 2.1 billion.
Aged individuals are more prone to the risk of low blood pressure, and at present, the population of geriatric individuals in most of the developed economies along with developing nations is increasing at a significant rate. The risk of hypotension normally increases with age due to the decline in blood flow to the heart, muscle and the brain, which often result in the plaque build-up in blood vessels. Hence, the rise in geriatric population is estimated to contribute towards the market demand for norepinephrine drug in future.
Drugs are given to save patients from life-threatening conditions and are used to deliver viability to serious condition patients. Except that there are a few major side effects associated with the norepinephrine drug present in the market. These might consist of sudden numbness, weakness, uneven heart rate, blue lips or fingernails, mottled skin, trouble breathing, problem with speech, severe headache, blurred vision and others. Moreover, stopping the norepinephrine drug might lead to the recurrence of low blood pressure (hypotension). On account of these, the market for the norepinephrine drugs is estimated to observe limited growth in future.
In-depth analysis of the global norepinephrine drug market includes the following segments:
On the basis of regional analysis, the global norepinephrine drug market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. Based on the region, the markets in North America and Europe are anticipated to hold significantly large market shares owing to the rising geriatric population in these developed nations. Additionally, the early adoption of cutting edge technology and innovations along with the considerable presence of the key market player in the region are further estimated to boost the market growth. On the other hand, norepinephrine market in Asia-Pacific region is likely to show an upward growth in the years to come. This can be accredited to the rising population of geriatric people in the region.
The global norepinephrine drug market is further classified on the basis of region as follows:
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization